Revance Therapeutics' Botox rival succeeds in late-stage trial

A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

from Reuters: Health News https://ift.tt/2PlxXsq
via IFTTT